When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KPTI - Karyopharm up 17% premarket on extension of review period for selinexor
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) is up 17% premarket on light volume in response to its announcement that the FDA has extended the review period 90 days for its marketing application seeing approval for selinexor, combined with dexamethasone, for the treatment of patients with relapsed/refractory multiple myeloma who have received at least three prior lines of therapy and whose cancer has not responded to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.
More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move,